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1  Abstract 
In Uganda, small scale pig production plays a major role for households to 
earn a living and to secure their access to meat. Piglet mortality due to diar-
rhoea-related dieseases is high. In an attempt to understand the underlying 
causes for this high mortality this study aims to investigate the role of trans-
missible gastroenteritis virus (TGEV) and is a part of a larger project con-
ducted at Makerere university in Uganda.   
A complicating factor in this investigation is the porcine respiratory corona-
virus (PRCV), a stabile mutant form of the TGE virus. The occurrence of this 
virus had shown to alter the impact of TGEV in e.g. Europe and North Amer-
ica. The interaction between these two viruses is discussed. Even porcine ep-
idemic diarrhoea (PED) is a coronavirus-induced disease of swine and reports 
on the presence of all three viruses in the world is reviewed. 
48 serum samples from adult pigs from the district of Gulu in Uganda were 
tested. The test used in this study is an enzyme-linked immunosorbent assay 
(ELISA) which is able to identify both TGEV and PRCV and to differentiate 
between these viruses. Test results for all samples showed to be negative. The 
result is discussed by considering a possible impact of the extensive heat-
inactivation on the samples as well as geography, climate and trade pattern of 
the district of Gulu in Uganda.  
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2  Sammanfattning 
I Uganda har grisproduktion i liten skala stor betydelse för att hushållen ska 
kunna få en inkomst och säkra sin tillgång till kött. Spädgrisdödligheten på 
grund av diarrésjukdomar är hög. I ett försök att förstå de underliggande or-
sakerna för denna höga dödlighet avser denna studie att undersöka betydelsen 
av transmissible gastroenteritis virus (TGEV) som en del av ett större projekt 
genomfört av Makerere universitetet i Uganda. 
En komplicerande faktor i denna undersökning är porcine respiratory coro-
navirus (PRCV), en stabil muterad form av TGE viruset. Förekomsten av 
detta virus har visat sig kunna förändra påverkan av TGEV i t.ex. Europa och 
Nord Amerika. Interaktionen mellan dessa två virus diskuteras. Även porcine 
epidemic diarrhoea (PED) är en coronavirus-inducerad grissjukdom och rap-
porter om förekomsten av dessa tre virus i världen återges. 
48 serum prover från vuxna grisar från Gulu-distriktet i Uganda testades. 
Testet som användes i denna studie är en enzyme-linked immunosorbent as-
say (ELISA) som kan identifiera både TGEV och PRCV och skilja mellan 
dessa två. Testet visade negativa resultat för samtliga prov. Resultatet disku-
teras med hänsyn till en möjlig påverkan av den omfattande värme-
inaktiveringen av proverna men även geografi, klimat och handelsmönster i 
Gulu-distriktet i Uganda.  
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3 Introduction 
3.1 Background 
In Uganda, small scale pig production is a common means for families to se-
cure access to meat and to provide an income (Nissen et al. 2011). Thus, 
owning pigs does not only improve a family`s economy through meat sales or 
as a savings instrument but even increases the social status of the household 
(Perry et al. 2002). In the countries of southern Africa it is often the women 
and children who own and take care of the animals (Chimonyo et al. 2005). 
Some of the Ugandan pigs are of Yorkshire-breed, imported to the country, 
but the majority of the pig population consists of indigenous breeds. Since 
the 1980s the pig population has increased tremendously in the whole coun-
try and the production of pig meat has grown more than tenfold from 1985 
until 2009 (FAOSTAT 2011). Especially in the north and northeastern parts 
of the country, pigs seem to have served as a replacement for the cattle lost in 
the wake of the civil strife during the 1970s (FAO 2004). The conditions un-
der which these animals are kept are very simple compared to the industrial-
ized environment of intensive pig farming in e.g. Europe. Approximately 
80% of all pigs are kept traditionally in Uganda, and the pig production of the 
developing countries relies to 70% on traditional production using mainly 
local breeds or cross-breeds (Lekule and Kyvsgaard 2003). Most of the pigs 
are kept by small household units (Ikwap 2011). The traditional ways of pig 
keeping in such small scale systems are free ranging, tethering or confine-
ment in simple sties (Lekule and Kyvsgaard 2003). The breeding is usually 
accomplished by mating the sows to a boar and they are usually brought to 
the boar for that purpose. Such breeder boars naturally represent an important 
source for spreading infections among the sows and other nearby pigs 
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(Wahlström et al. 1990). The greater part of the litter is usually lost due to 
diarrhoea-related diseases and the dominating disease agents involved are yet 
to be identified (Ikwap 2011).  
Livestock production in small scale enterprises and in the private sector is of 
vital importance in many developing countries, often contributing to a con-
siderable extent to the countries` food production. These small production 
units not only face a greater exposure to risk through a greater presence of 
disease and less disease control compared to production in industrialized 
countries, but also their capacity to bear risk is lower due to the small size of 
their livestock and the lack of economic reserves. An increase in efficiency of 
these livestock-producing activities would lead to an increase in income at 
the very source of the production (Perry et al. 2002).  
Pig farming in particular can be a very effective way to produce meat consid-
ering the fast reproduction cycle and the high feed conversion efficiency 
(Lekule and Kyvsgaard 2003). However, to achieve a high efficiency in pig 
farming in the described setting, one obviously crucial factor is to improve 
piglet survival. Therefore, an understanding of what are the most common 
fatal infectious diseases among piglets in Uganda is needed. At the Universi-
ty of Kampala, a PhD project currently focuses on the role of E.coli and Sal-
monella spp. for piglet mortality (Ikwap 2011). However, a broad spectrum 
of disease agents must be considered as possible differential diagnoses. In 
this context the present study aims to examine the prevalence of transmissible 
gastroenteritis virus (TGEV) as a possible agent for disease in the Ugandan 
pig population. TGEV is also an important differential diagnosis for E. coli-
associated diarrhoea. 
3.2 Coronavirus 
Both TGEV and porcine respiratory coronavirus (PRCV) are of the genus 
Coronavirus which is a member of the family Coronaviridae. The family of 
Coronaviridae is in turn included in the order Nidovirales (Saif 2011). There 
is a great number of different pathogenic coronaviruses which cause a wide 
variety of diseases among mammals and birds. These pathogens are subdi-
vided into three different groups and further into subgroups according to their 
genetic and serologic properties. TGEV and PRCV both belong to the same 
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group and subgroup, i.e. group 1a. Their virions, often spherical in shape, 
display large club-shaped spikes when seen under the electrone microscope 
(Saif 2011). The virions are enveloped and have an icosahedral internal core 
structure containing a helical nucleocapsid. Their surface exhibits a number 
of different structural proteins, surface glycoproteins, which the host immune 
system reacts to. Apparently, the neutralizing antibodies produced by the 
humoral immune response are mainly directed against the S protein (the ma-
jor spike glycoprotein), whereas the cellular immune response targets both 
the S protein and the N protein (nucleocapsid protein). Further known struc-
tural proteins of the coronavirus are the transmembrane glycoproteins M and 
E and in some coronaviruses also hemagglutinin esterase, HE (Saif 2011). 
The S protein, which is necessary for cell attachment and, at the same time, 
constitutes the main antigenic component of the virion, has some hypervaria-
ble domains enabling the formation of virus-escape mutants. In this way 
coronaviridae are able to evade the immune response of the host (Quinn et al. 
2011). 
3.3 TGE and PRCV 
Transmissible gastroenteritis (TGE) is a viral enteric disease that infects 
swine worldwide. It was reported for the first time in 1946. The disease is 
caused by a coronavirus called the transmissible gastroenteritisvirus (TGEV). 
In the 1980s a genetic variation of the TGE virus appeared, which was called 
the porcine respiratory coronavirus (PRCV) according to its tropism for the 
respiratory tract (Bohl 1989, Pensaert 1989, Saif and Sestak 2006).  
 
The appearance of the porcine respiratory coronavirus (PRCV) in Europe and 
the USA in the 1980s has changed the impact of TGEV. PRCV is a stable 
deletion mutant form of the TGE virus and antibodies against TGEV cross-
react with PRCV. Thus, infection with PRCV, leading to antibody produc-
tion, also seems to be protective against TGEV infection to a certain extent. 
In those European countries and parts of North America where PRCV occurs 
endemically, the impact of TGEV has declined (Saif and Sestak 2006). In 
fact, antiserum produced against TGEV neutralizes PRCV completely at the 
same neutralization titer (Pensaert 1989). This poses a challenge to diagnostic 
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methods that have to be able to distinguish antibodies against PRCV from 
those against TGEV (Saif and Sestak 2006). 
3.3.1 Epidemiology and pathogenesis of TGE  
TGE is transmitted in a fecal-oral pathway. It appears in an epidemic and an 
endemic form. In its epidemic form it is found in naïve herds, i.e. where no 
seropositive animals are found. Usually, animals of all ages are affected and 
the disease spreads quickly. Typically, infections occur during the winter-
time. The clinical signs vary with the age of the pigs. Piglets below 2-3 
weeks of age will be struck hardest by the disease. The TGE virus destroys 
the intestinal epithelium of the small intestine thereby impairing its absorp-
tive capacity. Vomiting, profuse, watery, yellowish diarrhoea containing un-
digested milk and, consecutively, loss of weight and dehydration occurs. The 
mortality rate for the youngest piglets is close to 100%. Piglets older than 3 
weeks often survive, but growth will be impaired. Growing and finishing pigs 
as well as sows usually show limited signs of disease, inappetence, diarrhoea 
and vomiting being the most common. Lactating sows, though, can become 
very sick with concurrent agalactia affecting her infected litter even more. 
The endemic form of TGE is found in herds where the virus persists. This is 
only possible in herds where there is a steady inflow of seronegative animals 
or continuous farrowing. Endemic TGE often follows an epidemic episode of 
TGE in the herd. The infection spreads slowly in contrast to the epidemic 
scenario and immune sows mitigate the clinical picture through the passive 
immunity passed on to their suckling piglets via their colostrum. The piglets 
show varying degrees of clinical disease and mortality normally lies under 
10-20% depending on their age at infection, the amount of maternal antibod-
ies ingested and a number of other factors. In such cases it will be a challenge 
to differentiate endemic TGE from other causes for endemic diarrhoea such 
as rotavirus diarrhoea, colibacillosis or porcine epidemic diarrhoea (PED) 
(Saif and Sestak 2006). 
3.3.2 Epidemiology and pathogenesis of PRCV 
PRCV infect pigs through airborne and contact transmission. Pigs of all ages 
are susceptible. In places with high density of swine farms and large herds 
the virus can cause infection over distances of several kilometers. PRCV in-
fection usually leads to milder disease with symptoms from the respiratory 
tract and the course of disease is often subclinical. These circumstances con-
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tributed to a rapid spread of the virus in Europe and many other parts of the 
world, even countries that had not previously been affected by TGEV. In 
many swine herds in Europe PRCV is regarded endemic today (Saif and 
Sestak 2006).  
3.3.3 Interactions between TGEV and PRCV 
The fact that antibodies against PRCV cross-react with TGEV, in connection 
with the observation that the impact of TGEV in positive herds declined after 
the introduction of PRCV, suggests that a PRCV-induced immunological re-
sponse could be protective against TGEV. This could be shown experimen-
tally for neonatal pigs (Wesley and Woods 1996). In another trial Wesley & 
Lager showed that the PRCV-priming of female piglets could induce a sec-
ondary immune response to TGEV shortly before farrowing, resulting in a 
higher litter survival rate compared to the non-primed gilts (Wesley and 
Lager 2003). Bernard et al. could report on the protective ability of prior 
PRCV infection against TGEV through lactogenic immunity (Bernard et al. 
1989). Still, a full protection against TGEV from PRCV infection cannot be 
expected per se (van Nieuwstadt et al. 1989, Bernard et al. 1989). The coro-
navirus is unstable by nature which claims for constant surveillance of the 
development of its different serotypes. Done mentions the need for further 
efforts to characterize the viruses since the protective properties of PRCV 
against TGEV may have decreased or TGEV might have become more viru-
lent after its unexpected return in Great Britain in 1996 (Done 2000). Even 
Pritchard et al. call for the evaluation of the emergence of new variants of 
viruses (Pritchard et al. 1999).   
3.4 PED – Porcine Epidemic Diarrhea 
Another disease that is caused by a coronavirus is porcine epidemic diarrhoea 
(PED). The clinical signs strongly resemble those of TGE with watery diar-
rhoea being the most obvious, but the piglet mortality tends to be lower as 
compared to TGE, normally lying around 50%. In some cases, though, it may 
be as high as 100%. Apparently, severe outbreaks with extremely high mor-
tality among newborn piglets were reported from Japan and Korea in recent 
years but have been rare in Europe. Signs of more pronounced abdominal 
pain and sometimes sudden deaths among adult and finisher pigs are clues 
that may help to differentiate PED from TGE. Probably, PED does not spread 
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as quickly between groups as TGE and it seems to be more persistent on a 
farm after the acute phase of an outbreak. Endemic infection is not unusual. 
The mode of transmission seems to be the same as for TGE, being mainly 
faecal-oral (Pensaert and Yeo 2006). 
3.5 TGEV, PRCV and PED in the world 
Until now, Sweden is considered free from TGEV and annual testing is un-
dertaken to confirm this status. PRCV was found in south-western Sweden 
already in 1986 and had spread over the whole country by 1993. Since then 
there have been 2 incidences where boars had tested positive for TGEV. Fur-
ther investigation could not confirm the presence of TGEV and it was as-
sumed that the results were due to instable mutations of PRCV. The fact that 
coronaviruses constantly mutate supports the assumption that frequently aris-
ing mutation variants of PRCV induce antibodies that are able to undermine 
the results of the test by cross-reacting with TGEV. This causes problems 
since the necessary follow-up testing to exclude TGEV takes time and delays 
the work flow of the boar stations with high costs for the pig industry as a 
whole in consequence (Berndtsson et al. 2006). Since its discovery, TGEV 
has been reported from countries all over the world (Rodriguez Batista et al. 
2005). In many European countries the prevalence of seropositive herds is 
almost 100% following the emergence of PRCV. Also in North America 
TGE is widely spread (Saif and Sestak 2006). TGE occurs both in a more si-
lent endemic form and as clinically evident disease outbreaks. If these differ-
ent appearances are linked to the presence or absence of PRCV infection is 
not completely clear (Pritchard et al. 1999).  Also PRCV seems to be endem-
ically spread in many European countries (Saif and Sestak 2006) with reports 
confirming its appearance in e.g. North America (Wesley et al. 1997), Japan 
(Miyazaki et al. 2010), Britain (Pritchard et al. 1999), Korea (Chae et al. 
2000) and Italy (Martelli et al. 2008). Reports from the African continent 
have been rather scarce. In 1999, Uganda apparently became the first country 
in Africa that reported the presence of TGE (Rodriguez Batista et al. 2005). 
Though, according to OIE statistics Uganda did not report TGE for the year 
2005 and for the following years until today no information has been availa-
ble. It remains unclear if the 1999 report was based on erroneous test results 
or if the disease disappeared again. Other African countries that reported the 
disease as “suspected but not confirmed” since 2005 are the Central African 
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Republic (2007 and 2008), Rwanda (2010) and Togo (2009). Only The Dem-
ocratic Republic of the Congo reported its TGE status as “confirmed infec-
tion but no clinical disease” for the years 2005, 2006 and 2007 (OIE 2011). 
Obviously, TGEV is present on the African continent but more detailed in-
formation on its prevalence in different African countries is not at hand. The 
prevalence pattern of PRCV and PEDV across the African countries also re-
mains rather unknown. 
3.6 Differential diagnoses to TGEV-diarrhoea and PED  
There are of course many causes for diarrhoea in young piglets and many of 
the pathologic agents induce disease during specific periods. The list below 
shows the common diarrhoeic diseases in a chronological order (Jacobson 
2003). 
 
• Neonatal diarrhoea during the first week of life when the piglets’ 
immunity depends completely on the maternal antibodies from the 
colostrum. 
o Colibacillosis (E.coli) 
o Transmissible gut gangrene (Clostridium perfringens Type C) 
o Clostridium perfringens Type A 
o Transmissible gastroenteritis (TGEV – Coronavirus) and por-
cine epidemic diarrhea (PEDV – Coronavirus) have the most 
severe impact on the animal during the early neonatal period. 
o New neonatal porcine diarrhoea (NNPD) with yet unknown eti-
ology (Svensmark 2009). 
 
• Diarrhoea during week 2 and 3 when the concentration of maternal 
antibodies has decreased and the production of own antibodies not 
yet fully developed. 
o Neonatal steatorrhoea (Isospora suis or rotavirus) 
o Secondary infection with E.coli 
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• Post-weaning diarrhoea during the first two weeks after weaning. 
Several predisposing factors such as changes in feed seem to play 
an important role during this period. 
o Enterotoxigenic E.coli (ETEC) 
 
• About 2-3 months after birth.  
o Spirochetal diarrhoea (Brachyspira pilosicoli) 
o Proliferative enteropathy (Lawsonia intracellularis) 
 
• Other diarrhoeic diseases with less pronounced connection to the 
pigs’ age. 
o Transmissible gastroenteritis (TGEV – Coronavirus) 
o Porcine epidemic diarrhoea (PEDV – Coronavirus) 
o Swine dysentery (Brachyspira hyodysenteriae) 
o Salmonellosis (Salmonella spp., especially S. Cholerasuis) 
 
During the past decade, also the Postweaning multisystemic wasting syn-
drome (PMWS) which is associated to the porcine circovirus type 2 (PCV2) 
has become a recognized etiology of diarrhoea in nursery and growing pigs 
(Segalés and Domingo 2002). 
 
To what extent the listed disease agents are relevant in small scale pig pro-
duction in the Ugandan setting is unknown, but this work may be a modest 
contribution to clarify the situation for at least TGEV/PRCV. 
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4 Materials and methods 
4.1 Experimental design 
The test used in this study is the SVANOVIR® TGEV/PRCV-Ab (Svanova 
Biotech AB, Uppsala, Sweden) which is able to detect and differentiate be-
tween TGEV- and PRCV-specific antibodies. Thus, an advantage with this 
test is that even the prevalence of PRCV could be detected which, as previ-
ously discussed, may alter the impact of a possible TGEV infection. The 
SVANOVIR® TGEV/PRCV-Ab is an enzyme-linked immunosorbent assay 
(ELISA). 
4.1.1 Sample collection and processing 
Blood samples were collected in 48 different households in Uganda in the 
district of Gulu. The households were usually situated several kilometers 
apart and a majority kept 1 to 3 adult pigs. Blood samples were collected 
from the jugular vein using sterile 21 gauge needles and sterile 4 ml vacu-
tainers without anticoagulant (BD-Playmouth, UK). The samples were then 
put on ice and transported in a cool-box to the veterinary office of the district. 
Here, the samples were refrigerated at 4°C overnight so a clot could develop. 
The following day the serum was separated, filled into sterile screw-capped 
micro-tubes (Sarstedt, Germany) and transported on ice in a cool-box to the 
laboratory at the Makerere University in Kampala where it was kept at -20°C. 
A total of 60 samples were taken whereof 59 came from adult pigs and one 
from a 3 week old diarrhoeic piglet. Seven of these samples showed severe 
haemolysis and were retained, and one sample was lost. The remaining 52 
samples were inactivated by heating at 56°C for 30 minutes and were then 
sent to the Swedish National Veterinary Institute (SVA) in Uppsala at 4°C. 
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Here, the samples were tested for Foot-and-mouth disease and African swine 
fever due to security routines. In this course 3 samples were identified as 
mildly positive for foot-and-mouth disease. These samples were removed 
from further analysis and the remaining samples were inactivated a second 
time, now at 70°C for 120 minutes. One other sample was removed because 
it did no longer contain any fluid. Finally, 48 samples, all from adult pigs, 
were used in the analysis. 14 of the samples were to a greater or lesser extent 
coagulated which made it difficult to retrieve the exact amount of fluid nec-
essary for the test. 
4.1.2 The ELISA test 
The ELISA test has been described as a useful test for the detection of TGE 
(Hohdatsu et al. 1987). There are different kinds of ELISA tests which func-
tion in slightly different ways (Tizard 2004). The SVANOVIR® 
TGEV/PRCV-Ab used in this study is an indirect blocking ELISA test. The 
TGEV-specific viral antigens are attached to the wells of a microtitre plate. 
Thereafter, the serum sample is added in pairs, i.e. in two different wells. 
Any antibodies against TGEV or PRCV present in the serum sample will 
bind to the antigen on the plate, hence the term “blocking”. If no such anti-
bodies are found in the serum sample the binding sites remain free (Fig. 1).  
Then, a solution containing monoclonal mouse IgG antibodies against TGEV 
is added to the first well and another solution containing monoclonal mouse 
IgG antibodies against TGEV/PRCV to the second well. If the respective 
binding sites of the antigen are still free, i.e. if no antibodies against the dis-
ease agents were present in the serum samples, the monoclonal mouse-
antibodies will attach to them. In the next step, enzyme-conjugated anti-
mouse IgG antibodies against the former monoclonal mouse IgG antibodies 
are added. These can only bind to epitopes on the monoclonal mouse IgG an-
tibodies. Since these epitopes are specific, unspecific binding of any swine-
antibodies will not occur. If the serum is free from TGEV or PRCV antibod-
ies, both the monoclonal mouse-antibodies, and in the next step the enzyme-
conjugated anti-mouse IgG antibodies, will have bound to the plate. In a final 
step a substrate is added that reacts with the enzyme and induces a colour 
change. 
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Figure 1 – The binding of mouse IgG antibodies and enzyme conjugated anti-mouse IgG 
antibodies to the antigen coated wells in the absence of specific swine antibodies against 
TGEV or PRCV in the serum sample (Chakravarthy 2011). 
 
Therefore, a strong colour change indicates a negative result, i.e. there were 
no antibodies against the disease agent present in the sample. In the absence 
of a colour change the test result will be positive, since the antibodies against 
TGEV or PRCV in the serum sample will have blocked the binding sites.  
 
A characteristic of the SVANOVIR® TGEV/PRCV-Ab is its ability to differ-
entiate between TGEV and PRCV antibodies. The fact that naturally existing 
antibodies against PRCV are able to cross-react with TGEV is used in the 
test. The test kit contains one solution with mouse IgG antibodies against 
TGEV (Anti-TGEV mAb solution) and another solution with mouse IgG an-
tibodies against PRCV which can also bind to TGEV (Anti TGEV/PRCV 
mAb solution). Each serum sample is added to a pair of wells, one for each of 
the two antibody solutions. The presence of swine TGEV antibodies in the 
serum samples will block the attached TGEV antigens in the wells of the mi-
crotitre plate for both the mouse antibodies against TGEV added to the first 
well, and for those against TGEV/PRCV added to the second well. Instead, 
swine PRCV antibodies in the serum samples will only block the attachment 
of the mouse antibodies against TGEV/PRCV added to the second well, leav-
ing the site for the mouse antibodies against TGEV in the first well free. Log-
ically, after the application of (1) the swine serum samples, (2) the respective 
mouse mAb solutions and (3) the enzyme conjugated anti-mouse antibodies, 
the test results must be interpreted in the following way (Table 1): 
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Attachment of mouse  
TGEV mAb in the first 
well containing sample x 
Attachment of mouse  
TGEV/PRCV mAb in the 
second well containing 
sample x 
Interpretation of the com-
bined results from well 1 
and 2 
Blocked (no colour change) Blocked (no colour change) TGEV+ 
Not blocked (colour change) Blocked (no colour change) PRCV+/TGEV- 
Not blocked (colour change) Not blocked (colour change) PRCV-/TGEV- 
 
Table 1 - Interpretation scheme for laboratory results 
 
In the first scenario, the blocking of both mouse TGEV mAb and mouse 
TGEV/PRCV mAb could have been caused by the presence of swine TGEV 
antibodies alone but it does not automatically exclude the presence of swine 
PRCV antibodies. Therefore, the result can only be interpreted as TGEV+ 
with certainty and the presence of swine PRCV antibodies can neither be ex-
cluded nor confirmed (Svanova Biotech AB 2011). 
 
4.1.3 Quantification of the results and validation of the test 
To quantify the color change and to be able to relate it to the positive and 
negative controls, the optical density (OD) is measured with a photometer at 
450 nm. Naturally, the negative control is supposed to give the greatest pos-
sible color change (maximum OD). The following formula is used to calcu-
late the percent inhibition (PI), i.e. the deviation of the OD of the sample 
from the greatest possible color change, namely the OD of the negative con-
trol, in relation to the OD of the negative control: 
 
 
𝑃𝐼 =  𝑂𝐷𝑛𝑒𝑔 𝑐𝑡𝑟𝑙  – 𝑂𝐷𝑠𝑎𝑚𝑝𝑙𝑒
𝑂𝐷𝑛𝑒𝑔 𝑐𝑡𝑟𝑙  × 100 
 
 17 
In the presence of a high concentration of blocking swine-antibodies in the 
serum the OD of the sample will be low, resulting in a high PI. In turn, the 
absence of any swine antibodies will result in a high OD showing a low PI. 
Test validity is examined by the application of control sera. The cut-off val-
ues for test validity according to the manufacturer are the following: 
 
• Negative TGEV/PRCV Control Serum: OD > 0.5 
• Positive TGEV Control Serum with Anti-TGEV mAb: PI > 60 
• Positive TGEV Control Serum with Anti-TGEV/PRCV: PI > 60 
• Positive PRCV Control Serum with Anti-TGEV mAb: PI < 15 
• Positive PRCV Control Serum with Anti-TGEV/PRCV: PI > 60 
 
The cut-off values for the interpretation of the results from the serum sample 
analysis are: 
 
• PI > 60  - positive 
• PI 45-60 – doubtful 
• PI < 45 – negative 
4.1.4 Sensitivity and specificity of the test 
The SVANOVIR® TGEV/PRCV-Ab has been tested at herd level and was 
found to provide a diagnostic sensitivity of 0.933 (95% confidence interval: 
0.779, 0.992) and a diagnostic specificity of 0.943 (95% confidence interval: 
0.86, 0.984) for the detection of TGEV which was considered good. It shall 
be mentioned that the test achieved a sensitivity of 100% for TGEV in exper-
imentally infected pigs 21 days after the day of infection. Before that, the test 
did not show consistently correct results. The ability of the test to diagnose 
animals infected early during an acute outbreak is therefore limited (Carman 
et al. 2002). No information could be found on the sensitivity or specificity of 
the test regarding the detection of TGEV in individuals or the detection of 
PRCV in general. 
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4.2 Laboratory analysis procedure 
The manual of the SVANOVIR® TGEV/PRCV-Ab test kit was followed in 
all details. Briefly, the procedure included the following steps: 
 
1. The plates were washed with PBS-Tween buffer 3 times according to 
the instructions. 
2. 100 µL each of the different control sera were added to the wells. 
3. 50 µL  of the serum samples together with 50 µL of PBS-Tween were 
added in duplicates to the wells. 
4. Incubation for 2 hours at +37°C. 
5. Step 1 was repeated. 
6. 100 µL of Anti-TGEV Solution was added to the first of the sample 
duplicates and 100 µL of Anti TGEV/PRCV was added to the second 
of the sample duplicates. Incubation for 30 minutes at room tempera-
ture. 
7. Step 1 was repeated. 
8. 100 µL of diluted HRP Conjugate Solution was added to the wells. 
Incubation for 30 minutes at room temperature. 
9. Step 1 was repeated. 
10. 100 µL of Substrate Solution was added to the wells. Incubation for 
30 minutes at room temperature. 
11. 50 µL Stop solution was added to the wells to stop the reaction. 
12. The OD was measured at 450 nm in a spectrophotometer within 15 
minutes after the application of the Stop Solution. 
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5 Results 
5.1 Controls 
All controls, both on the first and on the second microtitre plate indicated test 
validity. The test values for the controls are shown in the table below.  
 
 
Control serum mAb solution Plate 1 Plate 2 Cut-off value 
  Percent inhibition  
Pos. TGEV Anti TGEV + 74.8  + 70.0 PI > 60 
Pos. TGEV/PRCV Anti TGEV/PRCV + 83.7  + 79,4 PI > 60 
Pos. TGEV Anti TGEV -    0.1  -   0,3 PI < 15 
Pos. TGEV/PRCV Anti TGEV/PRCV + 90.3  + 87,2 PI > 60 
  Optical density  
Neg. TGEV/PRCV 1 Anti TGEV 1.487 1.039 OD > 0.5 
Neg. TGEV/PRCV 1 Anti TGEV/PRCV 1.312 1.054 OD > 0.5 
Neg. TGEV/PRCV 2 Anti TGEV 1.527 1.000 OD > 0.5 
Neg. TGEV/PRCV 2 Anti TGEV/PRCV 1.383 1.013 OD > 0.5 
 
Table 2 – Results of Control sera 
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5.2 Serum samples 
After measuring the optical density (OD) of each well the percent inhibition 
(PI) of each sample could be calculated. A cut-off value of less than 45 for 
the percent inhibition (PI) was indicative of a negative result and values with-
in the range of 45 to 60 were regarded doubtful. The calculated values for the 
PI of the analysed samples ranged from -11.8 to 24.2 (See Table 1 in the ap-
pendix for the values of each sample). These values clearly indicate negative 
results. This means that neither antibodies against TGEV nor against PRCV 
could be detected. No samples were regarded as doubtful.  
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6 Discussion 
6.1 Laboratory method 
Since it is the aim of this study to either confirm or reject the presence of a 
specific pathogen among a number of other possible pathogens that cause di-
arrhoea in piglets, the method used must be able to reliably identify TGEV. A 
diagnosis by clinical signs is therefore impossible. A biochemical diagnostic 
method is a more appropriate tool. The collection of samples had to be done 
in the field and therefore it would have been difficult to time each sample 
collection with an outbreak of diarrhoea among piglets. This would have 
been necessary because the detection of TGEV antigen requires that the sam-
ples are taken in an early stage of the disease (Saif and Sestak 2006). Another 
possibility would be to detect antibodies against TGEV. One advantage is 
that antibodies will be present in the blood for a long time after infection 
(Saif and Sestak 2006). This makes sample collection much easier. Even if 
the pathogen itself is not found, the presence of antibodies can be taken as a 
proof for previous infection and suggests an endemic TGEV status. 
6.2 Epidemiologic approach 
When individuals that do not show any clinical signs are tested for the pur-
pose of detecting a disease in the population, the measure is called a screen-
ing. From a clinical perspective, early diagnosis achieved through a screening 
measure should help to treat the condition more efficiently in order to make 
the screening worthwhile (Piantadosi 2005, Dohoo et al. 2010, Petrie and 
Watson 2006). The purpose of the screening performed in the present study is 
rather the attempt to identify a history of infection with TGEV among the 
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sows tested. The outline of this cross-sectional study was rather modest and a 
more sophisticated design of the study using e.g. paired samples would have 
been desirable to be able to more precisely determine the time of a possible 
infection and thereby the probability for the disease´s impact on the patho-
genesis. Still, considering that TGEV was not the main focus of the project 
and the scarcity of the resources, the study does contribute valuable infor-
mation. It will be one piece in a puzzle which in the end may give a picture of 
the spectrum of disease agents that actually contribute to Ugandan piglet 
mortality. Only then the question of efficient treatment or appropriate man-
agement measures can be addressed.  
6.3 Interpretation of the results 
The interpretation of the negative result for all 47 samples is not straight for-
ward. With regard to the quality and the treatment of the test material the 
possibility of false results needs to be discussed.  
6.3.1 Coagulation  
14 of the samples were marked as problematic with regard to their quality. In 
these cases it was either impossible or so difficult to receive the required 
amount (50 µL per well) of serum from the sample that the test operator de-
cided to make a remark. The coagulation/aggregation of serum may lead to a 
mechanical entrapment of particles, such as antibodies. This can prevent an-
tibodies from binding to the antigens attached to the plate consequently 
showing false negative results. A suggested practice to avoid this problem is 
to mix the clot with buffer solution and then dissolve it mechanically as well 
as possible. After centrifugation, the supernatant can be used as sample. In 
this way, the mechanical entrapment of antibodies present in the clot could be 
dissolved (M. Merza, personal communication). 
 
6.3.2 Heat treatment of the samples 
Heat inactivation of serum samples appears not to be regarded as harmful to 
antibody structure, in particular IgG. However, little scientific proof has been 
found to support this common opinion (Reynolds et al. 1977). Heat inactiva-
tion should still be considered as a possible source of false results since the 
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heat stability of immunoglobulin is not undisputed (Fan et al. 2009, Chantry 
et al. 2009). The process of denaturation of IgG appears to be complex with 
changes of e.g. the secondary structure occurring at 60°C and 70°C, respec-
tively. Depending on the temperature and the rate of the heating, the possibil-
ity of protein aggregation before the complete unfolding of the proteins also 
must be considered (Vermeer and Norde 2000). In the field testing of the 
SVANOVIR® TGEV/PRCV-Ab for repeatability of the results after heat in-
activation of the serum samples, a temperature of 56°C for a period of 30 
minutes was applied which did not affect the results negatively (Carman et al. 
2002). This is below the temperature that was used for the samples in this 
study and therefore it is difficult to discuss the possible heat treatment ef-
fects. 
6.4 Conclusion 
Even if the presence of TGEV/PRCV among the pig population in the district 
of Gulu in Uganda cannot be ruled out with certainty, the test results may still 
be interpreted as a hint to the absence of TGEV/PRCV. The fact that Uganda 
has reported TGEV in 1999, but never since, is staggering and must be eval-
uated in the light of test results and observations done before and after the 
report. Most of the quality issues regarding the samples could probably be 
solved by conducting the ELISA-testing in close connection to the sample 
collection. If the testing would be done at the laboratory of the Makerere 
University in Kampala the extensive heat-inactivation procedures that were 
undertaken in Sweden would not be necessary. The test could also be used 
more specifically in outbreak situations where a suspicion of TGEV or PRCV 
infection arises. All this would contribute to more reliable test results increas-
ing their usefulness. Therefore, it would be desirable that the colleagues in 
Kampala could operate the ELISA test used in this study themselves. If such 
a testing on site also would show negative results, confirming the absence of 
TGEV/PRCV, further studies could identify the entrance of TGEV/PRCV 
into the country if this was desirable.  
6.5 Outlook 
The prevalence and the impact of TGEV depend on various factors. Concur-
rent presence of PRCV is obviously one that can mitigate the impact of 
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TGEV. Other factors that might play a role may be trade, transport and cli-
mate. TGEV is described as sensitive to sunlight and warm climate. This may 
affect the virus` survival in the Ugandan countryside. In many parts of Africa 
there is no extensive trade or transport of animals such as pigs. Instead, pro-
duction, trade and consumption are often rather local. This may be an effec-
tive barrier for the diseases, especially TGEV which is transmitted by a fecal-
oral pathway. One obvious question is, of course, how a changed trade and 
transport pattern would alter the situation. The fact that TGEV has been re-
ported from the neighboring Democratic Republic of Congo and the increase 
in pig production in Uganda, even in a more industrialized manner, makes 
this question a less hypothetical one. Even if the district of Gulu is rather 
separated from the Democratic Republic of Congo by the Nile, the southwest 
of Uganda could be a potential path of entry for TGEV and might be worth-
wile to assess. In case of the establishment of TGEV in Uganda, several 
questions would arise, such as what impact the introduction of PRCV would 
have on the severity of TGEV outbreaks. Would PRCV decrease the severity 
of TGEV infection in the same way as it seems to have done in many other 
countries? The propensity to mutation of the coronavirus could lead to new 
variants (Pritchard et al. 1999) of TGEV or PRCV which might not show the 
same pattern of interaction. Another unreviewed study which was conducted 
in Hungary even suggests that it might not be the genetic properties of these 
viruses but rather the immune response of the pigs that play a role in the re-
emergence of TGE in some countries. The author mentions the possibility 
that the widespread porcine circovirus (PCV) with its immunosuppressive 
properties may inhibit antibody production against PRCV and TGEV 
(Andersson 2010). Vaccination against TGEV is possible though not fully 
protective (Tuboly et al. 2000). Besides, it is costly and may therefore be an 
unrealistic measure in Ugandan backyard pig production especially with re-
gard to African swine fever and foot-and-mouth disease being actual identi-
fied threats in the region.  
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Appendix 
 
Table 1 – Results of the ELISA test 
 
  
A B A-B ((A-B)/A)*100 
Sample no. 
 
OD neg. Control OD sample 
 
Percent Inhibition 
1 TGEV 1,42725 1,355 0,07225 5,062182519 
1 TGEV/PRCV 1,42725 1,364 0,06325 4,431599229 
2 TGEV 1,42725 1,473 -0,04575 -3,205465055 
2 TGEV/PRCV 1,42725 1,499 -0,07175 -5,027150114 
3 TGEV 1,42725 1,392 0,03525 2,469784551 
3 TGEV/PRCV 1,42725 1,43 -0,00275 -0,192678227 
5 TGEV 1,42725 1,364 0,06325 4,431599229 
5 TGEV/PRCV 1,42725 1,428 -0,00075 -0,052548607 
6 TGEV 1,42725 1,473 -0,04575 -3,205465055 
6 TGEV/PRCV 1,42725 1,402 0,02525 1,769136451 
8 TGEV 1,42725 1,478 -0,05075 -3,555789105 
8 TGEV/PRCV 1,42725 1,359 0,06825 4,781923279 
11 TGEV 1,42725 1,595 -0,16775 -11,753371869 
11 TGEV/PRCV 1,42725 1,345 0,08225 5,762830618 
12 TGEV 1,42725 1,432 -0,00475 -0,332807847 
12 TGEV/PRCV 1,42725 1,274 0,15325 10,737432125 
13 TGEV 1,42725 1,148 0,27925 19,565598178 
13 TGEV/PRCV 1,42725 1,222 0,20525 14,380802242 
15 TGEV 1,42725 1,467 -0,03975 -2,785076195 
 31 
15 TGEV/PRCV 1,42725 1,39 0,03725 2,609914171 
17 TGEV 1,42725 1,472 -0,04475 -3,135400245 
17 TGEV/PRCV 1,42725 1,264 0,16325 11,438080224 
18 TGEV 1,42725 1,434 -0,00675 -0,472937467 
18 TGEV/PRCV 1,42725 1,378 0,04925 3,450691890 
19 TGEV 1,42725 1,459 -0,03175 -2,224557716 
19 TGEV/PRCV 1,42725 1,134 0,29325 20,546505518 
20 TGEV 1,42725 1,497 -0,06975 -4,887020494 
20 TGEV/PRCV 1,42725 1,327 0,10025 7,023997197 
21 TGEV 1,42725 1,514 -0,08675 -6,078122263 
21 TGEV/PRCV 1,42725 1,384 0,04325 3,030303030 
22 TGEV 1,42725 1,435 -0,00775 -0,543002277 
22 TGEV/PRCV 1,42725 1,182 0,24525 17,183394640 
24 TGEV 1,42725 1,415 0,01225 0,858293922 
24 TGEV/PRCV 1,42725 1,235 0,19225 13,469959713 
25 TGEV 1,42725 1,41 0,01725 1,208617972 
25 TGEV/PRCV 1,42725 1,296 0,13125 9,196006306 
26 TGEV 1,42725 1,427 0,00025 0,017516202 
26 TGEV/PRCV 1,42725 1,327 0,10025 7,023997197 
27 TGEV 1,42725 1,46 -0,03275 -2,294622526 
27 TGEV/PRCV 1,42725 1,417 0,01025 0,718164302 
28 TGEV 1,42725 1,47 -0,04275 -2,995270625 
28 TGEV/PRCV 1,42725 1,4 0,02725 1,909266071 
29 TGEV 1,42725 1,438 -0,01075 -0,753196707 
29 TGEV/PRCV 1,42725 1,353 0,07425 5,202312139 
30 TGEV 1,42725 1,454 -0,02675 -1,874233666 
30 TGEV/PRCV 1,42725 1,318 0,10925 7,654580487 
31 TGEV 1,42725 1,439 -0,01175 -0,823261517 
31 TGEV/PRCV 1,42725 1,315 0,11225 7,864774917 
32 TGEV 1,42725 1,418 0,00925 0,648099492 
32 TGEV/PRCV 1,42725 1,317 0,11025 7,724645297 
33 TGEV 1,42725 1,4 0,02725 1,909266071 
33 TGEV/PRCV 1,42725 1,082 0,34525 24,189875635 
 32 
35 TGEV 1,42725 1,457 -0,02975 -2,084428096 
35 TGEV/PRCV 1,42725 1,334 0,09325 6,533543528 
36 TGEV 1,42725 1,444 -0,01675 -1,173585567 
36 TGEV/PRCV 1,42725 1,352 0,07525 5,272376949 
37 TGEV 1,42725 1,462 -0,03475 -2,434752146 
37 TGEV/PRCV 1,42725 1,42 0,00725 0,507969872 
38 TGEV 1,42725 1,506 -0,07875 -5,517603783 
38 TGEV/PRCV 1,42725 1,38 0,04725 3,310562270 
39 TGEV 1,42725 1,564 -0,13675 -9,581362761 
39 TGEV/PRCV 1,42725 1,42 0,00725 0,507969872 
40 TGEV 1,42725 1,427 0,00025 0,017516202 
40 TGEV/PRCV 1,42725 1,289 0,13825 9,686459975 
41 TGEV 1,42725 1,426 0,00125 0,087581012 
41 TGEV/PRCV 1,42725 1,242 0,18525 12,979506043 
42 TGEV 1,42725 1,436 -0,00875 -0,613067087 
42 TGEV/PRCV 1,42725 1,359 0,06825 4,781923279 
43 TGEV 1,42725 1,388 0,03925 2,750043791 
43 TGEV/PRCV 1,42725 1,386 0,04125 2,890173410 
46 TGEV 1,42725 1,401 0,02625 1,839201261 
46 TGEV/PRCV 1,42725 1,296 0,13125 9,196006306 
47 TGEV 1,42725 1,426 0,00125 0,087581012 
47 TGEV/PRCV 1,42725 1,225 0,20225 14,170607812 
48 TGEV 1,42725 1,469 -0,04175 -2,925205815 
48 TGEV/PRCV 1,42725 1,32 0,10725 7,514450867 
49 TGEV 1,42725 1,48 -0,05275 -3,695918725 
49 TGEV/PRCV 1,42725 1,354 0,07325 5,132247329 
51 TGEV 1,42725 1,365 0,06225 4,361534419 
51 TGEV/PRCV 1,42725 1,285 0,14225 9,966719215 
52 TGEV 1,42725 1,366 0,06125 4,291469609 
52 TGEV/PRCV 1,42725 1,318 0,10925 7,654580487 
54 TGEV 1,42725 1,374 0,05325 3,730951130 
54 TGEV/PRCV 1,42725 1,376 0,05125 3,590821510 
53 TGEV 1,42725 1,493 -0,06575 -4,606761254 
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53 TGEV/PRCV 1,42725 1,313 0,11425 8,004904537 
56 TGEV 1,42725 1,395 0,03225 2,259590121 
56 TGEV/PRCV 1,42725 1,348 0,07925 5,552636188 
57 TGEV 1,42725 1,4 0,02725 1,909266071 
57 TGEV/PRCV 1,42725 1,304 0,12325 8,635487826 
58 TGEV 1,42725 1,349 0,07825 5,482571379 
58 TGEV/PRCV 1,42725 1,228 0,19925 13,960413382 
59 TGEV 1,42725 1,4 0,02725 1,909266071 
59 TGEV/PRCV 1,42725 1,237 0,19025 13,329830093 
none TGEV 1,42725 1,283 0,14425 10,106848835 
none TGEV/PRCV 1,42725 1,141 0,28625 20,056051848 
 
